re: the unloved sector - biotech

The past year has been the worst year for mid-small biotech and medical device companies. However, looking forward, there will be some great advances from some Aussie biotech companies.

IMO, the biotech companies which might have great potentials to out-perform include,

(1) AAH: good take-over target as in the field of
monoclone antibodies'

(1) ACL: to receive the approval from FDA for its ANDA of
the generic form of GSK's heparin product;

(2) BTA: any outbreak of the flu or H-5N1 virus for be
the fortune of the company and if the Chairman
quits will be even better;

(3) CXS: submit complete NDA to FDA for the anti-cancer
product currently in Phase 3;

(4) IDT: unique and profitable company and have LT values;

(5) MBP: could turn into the next CIR if propertly use its
fund to invest into other biotech companies (not
directly into projects);


I hold position on BTA, CXS, and MBP